Part 4/15:
Her experience with AstraZeneca’s trial contract reveals a troubling pattern. Despite assurances that the drug company would cover all injury-related expenses, Brienne recounts being offered a mere $1,200 to settle her claims—a paltry sum considering her lifelong disability and ongoing medical expenses costing thousands each month. Such offers are insulting and dismissive, reflecting a broader pattern where injured patients are vastly undervalued and left to suffer without adequate support.